QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 maxim-group-upgrades-cns-pharma-to-buy-announces-20-price-target

Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announces $20 price target.

 cns-pharmaceuticals-q2-eps-642-beats-960-estimate

CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(6.42) per share which beat the analyst consensus estimate of $...

 cns-pharma-announces-1-for-12-reverse-split-of-its-common-stock

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in t...

 cns-pharmaceuticals-q4-eps-158-beats-600-estimate

CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of $...

 cns-pharma-prices-public-offering-of-395m-shares-at-1265shr-issuing-series-f-warrants

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in t...

Core News & Articles
Market-Moving News for May 13th
05/13/2025 11:11:57

COIN: 10% | Coinbase Global shares are trading higher it was announced that the company will join the S&P 500, effective be...

 maxim-group-downgrades-cns-pharma-to-hold

Maxim Group analyst Jason McCarthy downgrades CNS Pharma (NASDAQ:CNSP) from Buy to Hold.

 cns-pharmas-cancer-drug-misses-survival-goal-but-may-offer-fewer-side-effects

CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION